BR112022015505A2 - Composições e métodos para tratar doença de pompe - Google Patents
Composições e métodos para tratar doença de pompeInfo
- Publication number
- BR112022015505A2 BR112022015505A2 BR112022015505A BR112022015505A BR112022015505A2 BR 112022015505 A2 BR112022015505 A2 BR 112022015505A2 BR 112022015505 A BR112022015505 A BR 112022015505A BR 112022015505 A BR112022015505 A BR 112022015505A BR 112022015505 A2 BR112022015505 A2 BR 112022015505A2
- Authority
- BR
- Brazil
- Prior art keywords
- pompe disease
- methods
- compositions
- treat
- treat pompe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971930P | 2020-02-08 | 2020-02-08 | |
| US202063115975P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/017113 WO2021159092A1 (en) | 2020-02-08 | 2021-02-08 | Compositions and methods for treating pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015505A2 true BR112022015505A2 (pt) | 2022-09-27 |
Family
ID=74853758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015505A BR112022015505A2 (pt) | 2020-02-08 | 2021-02-08 | Composições e métodos para tratar doença de pompe |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12251430B2 (https=) |
| EP (1) | EP4100120A1 (https=) |
| JP (2) | JP7804582B2 (https=) |
| KR (1) | KR20220139936A (https=) |
| CN (1) | CN115715218A (https=) |
| AU (1) | AU2021216055A1 (https=) |
| BR (1) | BR112022015505A2 (https=) |
| CA (1) | CA3167091A1 (https=) |
| IL (1) | IL295415A (https=) |
| MX (1) | MX2022009753A (https=) |
| WO (1) | WO2021159092A1 (https=) |
| ZA (1) | ZA202209925B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021216055A1 (en) | 2020-02-08 | 2022-09-29 | Genzyme Corporation | Compositions and methods for treating pompe disease |
| MX2022016019A (es) | 2020-06-14 | 2023-04-10 | Genzyme Corp | Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| SI2457920T1 (en) | 2007-01-18 | 2018-02-28 | Genzyme Corporation | Oligosaccharides containing the amino acid group and their conjugates |
| CA3040973A1 (en) * | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| CN110124039A (zh) | 2011-05-16 | 2019-08-16 | 建新公司 | 使用甲氨蝶呤诱导免疫耐受性 |
| US10172924B2 (en) * | 2015-03-19 | 2019-01-08 | Translate Bio, Inc. | MRNA therapy for pompe disease |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| AU2021216055A1 (en) | 2020-02-08 | 2022-09-29 | Genzyme Corporation | Compositions and methods for treating pompe disease |
-
2021
- 2021-02-08 AU AU2021216055A patent/AU2021216055A1/en active Pending
- 2021-02-08 CA CA3167091A patent/CA3167091A1/en active Pending
- 2021-02-08 JP JP2022547874A patent/JP7804582B2/ja active Active
- 2021-02-08 KR KR1020227030889A patent/KR20220139936A/ko active Pending
- 2021-02-08 CN CN202180013438.1A patent/CN115715218A/zh active Pending
- 2021-02-08 BR BR112022015505A patent/BR112022015505A2/pt unknown
- 2021-02-08 MX MX2022009753A patent/MX2022009753A/es unknown
- 2021-02-08 WO PCT/US2021/017113 patent/WO2021159092A1/en not_active Ceased
- 2021-02-08 IL IL295415A patent/IL295415A/en unknown
- 2021-02-08 US US17/170,667 patent/US12251430B2/en active Active
- 2021-02-08 EP EP21709562.9A patent/EP4100120A1/en active Pending
-
2022
- 2022-09-06 ZA ZA2022/09925A patent/ZA202209925B/en unknown
-
2025
- 2025-02-13 US US19/053,240 patent/US20250319166A1/en active Pending
- 2025-08-22 JP JP2025138630A patent/JP2025166240A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021216055A1 (en) | 2022-09-29 |
| CN115715218A (zh) | 2023-02-24 |
| TW202142264A (zh) | 2021-11-16 |
| JP2025166240A (ja) | 2025-11-05 |
| KR20220139936A (ko) | 2022-10-17 |
| EP4100120A1 (en) | 2022-12-14 |
| CA3167091A1 (en) | 2021-08-12 |
| JP2023512783A (ja) | 2023-03-29 |
| JP7804582B2 (ja) | 2026-01-22 |
| WO2021159092A1 (en) | 2021-08-12 |
| MX2022009753A (es) | 2022-09-07 |
| US20250319166A1 (en) | 2025-10-16 |
| ZA202209925B (en) | 2026-01-28 |
| US12251430B2 (en) | 2025-03-18 |
| US20210244803A1 (en) | 2021-08-12 |
| IL295415A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230316B1 (ar) | N-(هيدروكسي ألكيل أريل (غير متجانس)) تترا هيدروفيوران كربوكساميدات كمعدلات لقنوات الصوديوم | |
| BR112022019532A2 (pt) | Conjugados de neodegrader | |
| CO2023005342A2 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| BRPI0608796B8 (pt) | método para a preparação de um extrato de planta compreendendo bacuquiol | |
| CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| BRPI1015539A2 (pt) | composições e métodos para tratamento de queimaduras | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| MX2022002053A (es) | Conjugados de il-15 y sus usos. | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| BR112022015505A2 (pt) | Composições e métodos para tratar doença de pompe | |
| BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
| EA202091205A1 (ru) | Композиции для терапии гипергликемии и сопутствующих состояний | |
| BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
| BR112022001866A2 (pt) | Derivados de amida híbridos de anfotericina b | |
| BR112021021728A2 (pt) | Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| BR112013032911A2 (pt) | leucotoxina e/d como um novo agente anti-inflamatório e microbicida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |